In pts who have CKD w confirmed eGFR of 20 60 and or albuminuria use an SGLT2 inhibitor to minimize progression of CKD and reduce CKD events and HF hospitalizations Note Glycemic benefits of SGLT2 inhibitors are reduced at eGFR

In pts who have CKD (w/ confirmed eGFR of 20-60 and/or albuminuria), use an SGLT2 inhibitor to minimize progression of CKD and reduce CKD events and HF hospitalizations. Note: Glycemic benefits of SGLT2 inhibitors are reduced at eGFR <45. [A]